Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Wdr43em1flox/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Wdr43em1flox/Cya

Common Name
Wdr43-flox
Product ID
S-CKO-15496
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-72515-Wdr43-B6J-VA
Status
Research and Development
When using this mouse strain in a publication, please cite “Wdr43-flox Mouse (Catalog S-CKO-15496) were purchased from Cyagen.”
cKO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
cKO Models
Basic Information
Strain Name
Wdr43-flox
Strain ID
CKOCMP-72515-Wdr43-B6J-VA
Gene Name
Wdr43
Product ID
S-CKO-15496
Gene Alias
Wrd43, mKIAA0007, 2610318G08Rik
Background
C57BL/6JCya
Gene Full Name
WD repeat domain 43
Modification
Conditional knockout
NCBI ID
72515 (Mouse)
Phenotype
MGI:1919765
Chromosome
Chr 17 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000047086
NCBI Transcript ID
NM_175639
Target Region
Exon 2~3
Size of Effective Region
~2.7 kb
Overview of Gene Research
Wdr43, also known as Utp5 in yeast, is an essential ribogenesis factor. It functions as a chromatin-associated RNA-binding protein (RBP) and release factor, modulating polymerase (Pol) II activity for pluripotency regulation. Wdr43 binds to promoter-associated noncoding/nascent RNAs, occupies gene promoters and enhancers, and interacts with the Pol II machinery [2]. It is also involved in ribosome biogenesis, which is crucial for normal development and cell function [3,5].

In colorectal cancer, Wdr43 knockdown significantly inhibits cell growth by arresting the cell cycle and enhancing the effect of oxaliplatin chemotherapy both in vitro and in vivo. Mechanistically, c-MYC promotes Wdr43 transcription upon oxaliplatin stimulation, and Wdr43 enhances p53 ubiquitination by MDM2, reducing p53 protein stability and promoting cancer cell proliferation and chemoresistance [1].

In non-small cell lung cancer, knocking down Wdr43 expression significantly impairs cell migration, proliferation, and causes cell-cycle arrest in the G1 phase [4].

In colorectal cancer, Wdr43 knockdown increases apoptosis, inhibits cell proliferation, migration, and invasion in vitro and reduces tumorigenesis in animal models, and its effect can be partially reversed by overexpressing vimentin [6].

In conclusion, Wdr43 plays a significant role in ribosome biogenesis and pluripotency regulation. In disease conditions, especially in cancers like colorectal and non-small cell lung cancer, Wdr43 promotes tumor progression. The study of Wdr43 through loss-of-function experiments in cell lines and animal models has provided valuable insights into its role in cancer development, suggesting it could be a potential therapeutic target.

References:
1. Di, Yuqin, Jing, Xiaoqian, Hu, Kunhua, Wang, Ziyang, He, Weiling. 2022. The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity. In Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 66, 100909. doi:10.1016/j.drup.2022.100909. https://pubmed.ncbi.nlm.nih.gov/36525936/
2. Bi, Xianju, Xu, Yanhui, Li, Tong, Li, Pilong, Shen, Xiaohua. 2019. RNA Targets Ribogenesis Factor WDR43 to Chromatin for Transcription and Pluripotency Control. In Molecular cell, 75, 102-116.e9. doi:10.1016/j.molcel.2019.05.007. https://pubmed.ncbi.nlm.nih.gov/31128943/
3. Sondalle, S B, Baserga, S J, Yelick, P C. 2016. The Contributions of the Ribosome Biogenesis Protein Utp5/WDR43 to Craniofacial Development. In Journal of dental research, 95, 1214-20. doi:10.1177/0022034516651077. https://pubmed.ncbi.nlm.nih.gov/27221611/
4. Sun, Haijun, Sun, Qi, Qiu, Xie, Li, Aimin, Dai, Jianhua. 2022. WD repeat domain 43 promotes malignant progression of non-small cell lung cancer by regulating CDK2. In The international journal of biochemistry & cell biology, 151, 106293. doi:10.1016/j.biocel.2022.106293. https://pubmed.ncbi.nlm.nih.gov/36041702/
5. Zhao, Chengtian, Andreeva, Viktoria, Gibert, Yann, Baserga, Susan, Yelick, Pamela C. 2014. Tissue specific roles for the ribosome biogenesis factor Wdr43 in zebrafish development. In PLoS genetics, 10, e1004074. doi:10.1371/journal.pgen.1004074. https://pubmed.ncbi.nlm.nih.gov/24497835/
6. Li, Zijian, Feng, Min, Zhang, Jie, Guan, Wenxian, Wang, Hao. 2021. WD40 repeat 43 mediates cell survival, proliferation, migration and invasion via vimentin in colorectal cancer. In Cancer cell international, 21, 418. doi:10.1186/s12935-021-02109-1. https://pubmed.ncbi.nlm.nih.gov/34372874/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research